Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
about
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectivesBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaSequence of treatment in locally advanced and metastatic renal cell carcinomaCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusSunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium studyNovel agents in renal carcinoma: a reality check.PinX1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis by suppressing MMP-2 via NF-κB-dependent transcription.Contrasting effects of sunitinib within in vivo models of metastasis.Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancerChanges in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Cellular effects induced by 17-β-estradiol to reduce the survival of renal cell carcinoma cells.Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma.Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma.Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Molecular targets on the horizon for kidney and urothelial cancer.Emerging antiangiogenics for renal cancer.Thrombocytosis as a prognostic marker in gastrointestinal cancers.Future perspectives for mTOR inhibitors in renal cell cancer treatment.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma.Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma.Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.The treating scenario in genitourinary oncology: what is new? Part 2.Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
P2860
Q26751341-976D5F0C-A716-4963-BED4-74B3DE24DDC6Q26766240-A0CAE3AC-D073-4CB3-9802-37F6DB6A39BFQ26773653-C6068549-0F41-4681-890C-758EB98C6268Q27001560-F8C58792-92CC-4C48-9D16-FE593F07D7FFQ33417828-12DD1CF8-628F-489F-B229-B68D8793C213Q34351372-27CBE0D6-1C69-4DF8-9875-167E2981A02CQ34577000-82232F50-F0E9-42C9-8A79-F851C3249923Q34658095-CA7262D3-FFA2-4320-92C3-1EC07450B93FQ35144490-AB007A7A-E58A-4C1E-A923-8787C3243FF3Q36061173-D3035436-BD15-4888-963B-692A91477EE0Q36356348-53324FFB-56A0-4D7E-A4ED-CE90BF6F189CQ36394262-30FEBD04-F0CA-45C0-993F-CF4DAD8A88D7Q36999374-0A1F8A9F-5C09-4333-A1B5-F38E5BC20771Q37185773-A9CC4760-523D-474C-9159-6D4F40257CADQ37294496-E19A3C96-496D-48DD-AEBF-4E9A6D633940Q37590941-755FDC77-31EF-46B5-A43B-43A4F56593AFQ37712156-A7983022-3D4E-4046-8E5C-CC0AF7EB067FQ38048822-69D8CA67-AB2B-4ED2-88CA-54AEA9BB7CB1Q38062554-7844A7D8-2682-4826-B8B7-BD6EA1C82B97Q38068584-37909368-4216-4DA9-95D8-A807788C0078Q38132039-C80AE639-B79D-43F1-8542-FF20617105E9Q38166015-2DB3EF74-9FCC-466F-AD24-5796F09DFDC8Q38190956-FE58D0D6-AEF4-48C3-94A9-EBBB51506F9AQ38372445-961494CF-9443-4C61-91C6-5A8769FA3F45Q38430335-CC78EB9D-AD3C-4BCF-8350-6B98F5028012Q38442897-770C9BF3-1DF2-476C-8E1F-EB51257E4BFFQ38485779-451571A5-D69D-4594-B78D-A0573D1F936DQ38546217-4C03CB03-55AB-4CB2-9055-9465D07EF01EQ38656760-41F7118B-398A-4ED3-8836-CABA60665512Q38706677-056D0B23-728C-4185-A390-95C27459D8C6Q38868038-3CE05060-A0D5-4F10-B722-1E04A1C29E2BQ38889516-25A5F74F-8AEF-4D5D-830D-C9C41714DE32Q39008859-B67108F6-4C52-4FDD-8026-64F3804A44A4Q40826012-B3CF561D-A008-41E6-83AB-8446C0C1B758Q41145898-7FD2F07A-DE74-4A1B-AA47-73369909D2F8Q41897121-83AB276F-1324-4486-91D3-B343E79DD8D1Q42317002-C6FAE6ED-7FC8-4912-8ED1-2914C6A54F1FQ45968992-91127922-58EF-4019-94D2-7EAE5283458FQ47155568-412524F3-3463-406E-9F56-F655E64505F1Q47265255-2781A812-522D-4421-924C-C6536A5DB7DA
P2860
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Primary anti-vascular endothel ...... actors, and subsequent therapy
@ast
Primary anti-vascular endothel ...... actors, and subsequent therapy
@en
Primary anti-vascular endothel ...... actors, and subsequent therapy
@nl
type
label
Primary anti-vascular endothel ...... actors, and subsequent therapy
@ast
Primary anti-vascular endothel ...... actors, and subsequent therapy
@en
Primary anti-vascular endothel ...... actors, and subsequent therapy
@nl
prefLabel
Primary anti-vascular endothel ...... actors, and subsequent therapy
@ast
Primary anti-vascular endothel ...... actors, and subsequent therapy
@en
Primary anti-vascular endothel ...... actors, and subsequent therapy
@nl
P2093
P2860
P356
P1433
P1476
Primary anti-vascular endothel ...... actors, and subsequent therapy
@en
P2093
C Kollmannsberger
M J Mackenzie
T K Choueiri
U N Vaishampayan
P2860
P304
P356
10.1093/ANNONC/MDR533
P577
2011-11-05T00:00:00Z